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Abstract
Hepatitis C virus (HCV) is a main risk factor for liver cirrhosis and hepatocellular carcinoma, particularly to those patients with
chronic liver disease or injury. The similar etiology leads to a high correlation of the patients suffering from the disease of
liver cirrhosis with those suffering from the disease of hepatocellular carcinoma. However, the biological mechanism for the
relationship between these two kinds of diseases is not clear. The present study was initiated in an attempt to investigate
into the HCV infection protein network, in hopes to find good biomarkers for diagnosing the two diseases as well as gain
insights into their progression mechanisms. To realize this, two potential biomarker pools were defined: (i) the target genes
of HCV, and (ii) the between genes on the shortest paths among the target genes of HCV. Meanwhile, a predictor was
developed for identifying the liver tissue samples among the following three categories: (i) normal, (ii) cirrhosis, and (iii)
hepatocellular carcinoma. Interestingly, it was observed that the identification accuracy was higher with the tissue samples
defined by extracting the features from the second biomarker pool than that with the samples defined based on the first
biomarker pool. The identification accuracy by the jackknife validation for the between-genes approach was 0.960,
indicating that the novel approach holds a quite promising potential in helping find effective biomarkers for diagnosing the
liver cirrhosis disease and the hepatocellular carcinoma disease. It may also provide useful insights for in-depth study of the
biological mechanisms of HCV-induced cirrhosis and hepatocellular carcinoma.
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Introduction
Hepatitis C virus (HCV) is an important risk factor for liver
cirrhosis and hepatocellular carcinoma [1,2,3,4]. The pathogenesis
of these diseases is a multi-step process, including hepatocellular
damage and apoptosis, wound-healing responses, inflammatory
responses, and hepatocellular regeneration [5]. It is also well
known that liver cirrhosis has high potential to lead to
hepatocellular carcinoma, especially in the case of HCV-induced
cirrhosis [6]. Thus, these two diseases are often correlated with
each other, and diagnosis of cirrhosis and HCC at early stages
remains challenging [7]. The detailed mechanisms of HCV-
induced cirrhosis and hepatocellular carcinoma are unknown [4].
Rapid detection of liver cirrhosis or hepatocellular carcinoma will
help provide a timely and appropriate treatment so as to enhance
the survival rate of the patient [8,9]. Understanding of the detailed
mechanisms of disease progression can help in developing
therapeutic strategies. For example, after revealing the roles of
vascular endothelial growth factor receptor (VEGFR) and
fibroblast growth factor receptor signaling in hepatocellular
carcinoma, their inhibitor Brivanib provides a novel therapeutic
treatment against hepatocellular carcinoma [10]. To find effective
diagnosis methods for cirrhosis and hepatocellular carcinoma and
reveal their mechanisms, knowledge of large-scale HCV infection
networks from high-throughput experimental techniques is very
useful [11,12,13]. In the traditional biomarker studies, the selected
biomarkers were often quite different for different studies, and only
had a very small overlap [14,15]. Since there was little
concordance among the reported markers, it was hard to identify
high-quality biomarkers.
In our approach, we defined two potential biomarker pools,
which we will refer to as the ‘‘target genes’’ and ‘‘between genes’’.
The target genes were the human genes associated with the HCV
proteins. The between genes were the human genes that were on
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,     the shortest paths between the target genes in the protein
interaction network. Such two sets of genes have strong biological
rationales in correlation with the risk factors that cause liver
cirrhosis and hepatocellular carcinoma. Utilizing the concrete
HCV-human interaction information would help to exclude the
false positive markers. Selecting biomarkers from the target genes
and the between-genes would not only make them have an
intrinsic correlation with liver cirrhosis and hepatocellular
carcinoma diagnosis, but also provide useful information for
HCV-induced liver transformation. Indeed, we found that the
information of the between-genes among the target genes of HCV
can be used to better classify the liver cirrhosis and hepatocellular
carcinoma samples than the target genes of HCV. These findings
suggest that the interactions between the target genes of HCV are
more important than the target genes themselves in triggering liver
cirrhosis and hepatocellular carcinoma. It was observed by
examining the selected biomarkers that some meaningful corre-
lations did exist among liver cirrhosis, hepatocellular carcinoma,
and the genes involved in other cellular processes. The biomarkers
found in this study may be of use for diagnosing HCV-induced
cirrhosis and hepatocellular carcinoma, as well as for revealing
their pathogenic mechanisms.
Methods
According a recent review [16], to develop a useful model or
predictor for biological systems, the following procedures were
usually needed to consider: (i) benchmark dataset construction or
selection; (ii) mathematical formulation for biological samples that
can truly reflect their intrinsic correlation with the target to be
predicted; (iii) introducing or developing a powerful algorithm (or
engine) to operate the prediction; (iv) properly performing cross-
validation tests to objectively evaluate the anticipated accuracy of
the predictor. Below, let us elaborate how to deal with these
procedures.
Benchmark dataset: gene expression profiles of normal,
cirrhotic, and carcinoma liver tissues
The benchmark dataset used in this study contained 124 tissue
samples, of which 19 samples were from normal persons, 58 from
the cirrhotic patients, and 47 from the hepatocellular carcinoma
patients. The corresponding gene expression profiles for the 19
normal, 58 cirrhotic, and 47 hepatocellular carcinoma (HCC) liver
tissue samples were from Mas’s work [17] at http://www.ncbi.
nlm.nih.gov/projects/geo/query/acc.cgi?acc=GSE14323. The
data from the two Affymetrix platforms, HG-U133A and HG-
U133A 2.0, were combined by means of the R package
matchprobes [18]. The Robust Multi-Array (RMA) method was
utilized to process the data [19]. Duplicated probes for each gene
were averaged and the processed data were normalized with the
quantile method [20]. There were a total of 12,936 genes, and
their expression levels were measured in the 124 samples.
According to the set theory, the benchmark dataset S can be
formulated as
S~S1|S2|S3 ð1Þ
where the subset S1 contains 19 normal liver tissue samples, subset
S2 contains 58 cirrhotic liver tissue samples, subset S3 contains 47
hepatocellular carcinoma liver tissue samples, and | represents
the symbol for ‘‘union’’.
Tissue sample representation
To develop a powerful statistical prediction method for
identifying the attributes of biological samples, one of the most
important steps is to extract the core and essential features of the
samples that are closely correlated with the target to be identified
[21]. According to Eq. 6 of [16], the representation of a tissue
sample, or its feature vector, can be formulated as
T~ y1 y2     yu     yV ½ 
tran ð2Þ
where T represents the tissue sample, tran the transpose operator,
the components y1, y2, … and V will depend on how to extract
the desired information from the tissue sample, as will be
elaborated below.
Hepatitis C virus network
In de Chassey et al.’s study, they identified 481 interactions
between HCV and human proteins by the yeast two-hybrid
experiments and literature mining [22]. Here, we used the
interactions identified by them to construct the hepatitis C virus
– human network. The human-protein interaction networks we
used were downloaded from STRING [23]. STRING is a
comprehensive protein-protein interaction network and the
interactions in STRING include physical and functional associa-
tions between proteins derived from previous knowledge, genomic
context, conserved coexpression and high-throughput experiments
[23]. The weight of STRING network was defined as one minus
the confidence score.
The target genes of HCV and the between genes among
target genes of HCV
We defined two potential biomarker pools that have strong
biological rationales associated with the culprits of the liver
cirrhosis and hepatocellular carcinoma: (i) the target genes, and (ii)
the between-genes. Figure 1 shows the relationship among the
HCV proteins, target genes and the between genes. The target
genes were the human target genes of the HCV proteins. The
Figure 1. The relationship among the HCV proteins, the target
genes and the between genes. The yellow node (V1, V2) are HCV
proteins. The target genes (blue nodes, T1, T2 and T3) were the human
target genes of HCV proteins. The between genes (red nodes, B1, B2
and B3) were human genes that were on the shortest paths between
target genes in protein interaction network. The grey nodes were other
human proteins that were neither target genes, nor between genes.
doi:10.1371/journal.pone.0034460.g001
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paths between the target genes in the STRING network.
There were 290 target genes associated with the 10 HCV
proteins that were measured in our dataset and can be mapped
onto the STRING network.
To obtain the between-genes among the target genes of HCV,
we linked each pair of the target genes of the 10 HCV proteins by
searching the shortest paths between them. The technique we used
to find the shortest path was Dijkstra’s algorithm [24,25,26]. The
genes on the shortest paths between the target genes of HCV were
defined as the between-genes among the target genes of HCV.
There were 684 between-genes among the target genes of HCV.
Accordingly, if using the features of the target genes to represent
the tissue samples, Eq. 2 will become a vector with V~290
components; i.e.,
T~ y1 y2     y260 ½ 
tran ð3Þ
If using the features of the between genes to represent the tissue
samples, Eq. 2 will become a vector with V~684 components; i.e.,
T~ y1 y2     y684 ½ 
tran ð4Þ
Minimum Redundancy Maximum Relevance (mRMR)
In this study, we used the mRMR (Minimum Redundancy
Maximum Relevance) approach [27] to select the genes that can
be used for classification of liver cirrhosis and hepatocellular
carcinoma from the 290 target genes and the 684 between genes,
respectively. The advantage of using the mRMR method here is
that it can balance the minimum redundancy and the maximum
relevance. The maximum relevance would guarantee selecting
those features with the most contributions to the classification,
while the minimum redundancy would guarantee excluding those
features that had already been covered by the selected features.
During the selecting process, one feature at a time was selected by
mRMR into the selected list. In each round, a feature with the
maximum relevance and minimum redundancy was selected. As a
result, we obtained an ordered list of features. The mRMR
program is available at http://penglab.janelia.org/proj/mRMR/.
Nearest neighbor algorithm
In this study, the nearest neighbor algorithm (NNA) [28,29,30]
was used as a prediction engine to identify sample classes as
implemented in the NNA program (available at http://pcal.
biosino.org/NNA.html). Owing to its good performance and
simple-to-use feature, the NNA classifier is quite popular in
pattern recognition and has been widely used to deal with varieties
of biological problems (see, e.g., [31,32,33,34,35,36,37,38,39,40,
41,42]). According to the NNA rule, the query sample should be
assigned to the same class as the one in the training dataset that is
nearest to the query sample. In case there are two or more samples
in the training dataset that have exactly the same closest distance
to the query sample, then the query sample will be randomly
assigned to any one of their classes although this kind of case rarely
happens. There are many different metrics to measure the
‘‘nearness’’, such as Euclidean distance [42], Hamming distance
[43], and Mahalanobis distance [44,45,46]. In the current study,
the following equation was adopted to measure the nearness
between two samples:
D(T1,T2)~1{
T1:T2
T1 kk : T2 kk
ð5Þ
where T1 and T2 are two vectors representing two samples (cf. Eq.
1), T1:T2 is their dot product, T1 kk and T2 kk are their moduluses.
The smaller the D(T1,T2), the more similar the two samples are.
For a concise formulation of the NNA classifier, see Eq. 17 of [16];
for an intuitive illustration of how the NNA classifier works, see
Fig. 5 of [16].
Jackknife test
In statistical prediction, the following three cross-validation
methods are often used to examine a predictor for its effectiveness
in practical application: independent dataset test, subsampling test,
and jackknife test [43]. However, as illustrated in [47] and
demonstrated by Eq. 50 of [31], among the three cross-validation
methods, the jackknife test is deemed the least arbitrary that can
always yield a unique result for a given benchmark dataset, and
hence has been increasingly used by investigators to examine the
accuracy of various predictors (see, e.g., [33,34,35,37,38,40,42,
48,49,50,51,52,53,54,55]. Accordingly, in this study, the predic-
tion model was examined by the jackknife test, also known as
leave-one-out cross-validation (LOOCV) test. During the course of
jackknife test, each sample in the benchmark dataset was in turn
singled out as the prediction target and the rest of the samples were
used to train the prediction model. The following equation was
used to reflect the prediction accuracy:
Q~
Y1zY2zY3
N1zN2zN3
ð6Þ
where Y1, Y2 and Y3 represent the numbers of correctly predicted
events for the ‘‘normal’’, ‘‘cirrhotic’’, and ‘‘hepatocellular
carcinoma’’ tissue samples, respectively; while N1, N2 and N3
stand for the numbers of ‘‘normal’’, ‘‘cirrhotic’’, and ‘‘hepatocel-
lular carcinoma’’ samples investigated, respectively.
Incremental feature selection (IFS)
Based on the ranked features according to their importance
evaluated by the mRMR approach, we used Incremental Feature
Selection (IFS) [56,57] to determine the optimal number of
features. During the IFS procedure, features in the ranked feature
set were added one by one from higher to lower rank. A new
feature set was composed when one feature had been added. Thus
N feature sets would be composed for the N ranked features. The i-
th feature set is given by
Si~ f1,f2,   ,fi fg (1ƒiƒN) ð7Þ
For each of the N feature sets, an NNA classifier was constructed
and examined using the jackknife test on the benchmark dataset.
By doing so we obtained an IFS table with one column for the
index i and the other columns for the prediction accuracy. Thus,
we could obtain the optimal feature set (Soptimal), with which the
predictor would yield the highest prediction accuracy.
Results and Discussion
The IFS results of target genes and between genes
By analyzing the gene expression profiles for the normal,
cirrhotic, and hepatocellular carcinoma liver tissue samples with
the mRMR method, we ranked the 290 target genes and 684
Classification of Liver Cirrhosis and Cancer
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hepatocellular carcinoma classification. Subsequently, we selected
the optimal gene set from the aforementioned ranked genes by
means of the IFS procedure. The IFS curves of the target genes
and between genes are shown in Figure 2, where the blue curve is
the IFS curve for the target genes and the highest accuracy was
0.944 with 155 genes. The red curve is the IFS curve for the
between genes and the corresponding highest accuracy was 0.960
with 162 genes. The IFS tables for the target genes and the
between genes were given in Table S1 and Table S2,
respectively. As shown in Figure 2, the accuracies for the
between genes were always higher than those for the target genes.
The selected 155 target genes and selected 162 between genes can
be found in Table S3 and Table S4, respectively. Furthermore,
an integrated system containing 916 genes was constructed by
combining the set of 290 target genes and the set of 684 between
genes. The IFS curve for such 916 target/between genes was
shown in Figure S1, from which we can see that the
corresponding highest accuracy was 0.968 and IFS curve of the
combined gen set was twisted with the IFS curve of the between
genes, indicating that no significant improvement for the
prediction was observed by integrating the target genes with the
between genes.
Analysis of the selected target genes and between genes
with HCV
It is known that HCV is primarily comprised of a single long
open-reading-frame encoding an approximately 3000-amino-acid-
long protein that is cleaved into three mature structural proteins
(CORE, E1, E2), six non-structural proteins (NS2, NS3, NS4A,
NS4B, NS5A, NS5B) and a small membrane protein (p7) [58,59].
To analyze which HCV protein can be related to liver cirrhosis
and hepatocellular carcinoma, we calculated the number of the
selected target genes for each HCV protein and the number of the
selected between genes for each of the HCV protein pairs. Shown
in Figure 3 is the number of selected target genes for each of the
HCV proteins. According to Figure 3, HCV proteins NS3, NS5A
and CORE are the most important ones because they were
observed interacting with many target genes in the selected
optimal target gene set. The number of the selected between genes
for each of the HCV protein pairs is shown in Figure 4, from
which we can see that the following pairs are involved with more
than 80 selected between genes and hence are more important:
NS3_NS5A, CORE_NS3, F_NS3, E2_NS3, NS3_NS5B, COR-
E_NS5A and E1_NS3. Among the above seven pairs, NS3
appeared six times; NS5A, two times; CORE, two times. The
outcome is quite similar to that of the target gene. Although there
were only 19 genes overlapped between the selected 155 target
genes and the selected 162 between genes, the results were quite
robust for the HCV protein level. This is because it was found that
NS3, NS5A and CORE were important from both the analysis of
the selected target genes for each of the HCV proteins and the
analysis of the selected between genes for each of the HCV protein
pairs. NS3 and NS5A are both non-structural proteins which are
responsible for the function of replication and for packaging the
viral genome into capsids [58]. NS3 is a bifunctional protease/
helicase [60], and is associated with the tumour suppressor p53
[61]. NS3 has been intensely studied as drug targets [62].
Figure 2. The IFS curves of target genes and between genes. In the IFS curve, the X-axis is the number of genes used for classification, and the
Y-axis is the prediction accuracies of nearest neighbor algorithm evaluated by the jackknife test (or LOOCV). The blue curve is the IFS curve of target
genes and the highest accuracy was 0.944 with 155 genes. The red curve is the IFS curve of between genes and the highest accuracy was 0.960 with
162 genes.
doi:10.1371/journal.pone.0034460.g002
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reported that an inhibitor of HCV NS5A could suppress virus
replication in clinical trials [63]. CORE protein plays an essential
role in the formation of virion and it interacts with other HCV
proteins [64,65].
Comparison of the selected target genes and between
genes with the known hepatocellular carcinoma genes
To compare the selected target genes and the between genes
with the known hepatocellular carcinoma genes, an enrichment
analysis was performed for the 155 selected target genes and the
162 selected between genes on the OncoDB.HCC [66] genes.
OncoDB.HCC is a comprehensive database of hepatocellular
carcinoma related genes [66]. The results thus obtained for the
155 selected target genes and the 162 selected between genes on
OncoDB.HCC genes are shown in Table 1, from which we can
see that the 162 selected between genes were significantly (having
hypergeometric test p value=1.25E-05) more enriched with the
OncoDB.HCC genes than the 155 selected target genes. Besides,
the selected between genes also had greater overlapping with the
OncoDB.HCC genes in comparison with the 155 selected target
genes.
The biological meanings of the selected target genes and
the between genes
To reveal the biological meanings, we performed the KEGG
enrichment analysis on the 155 selected target genes and the 162
selected between genes using GeneCodis [67,68]. Shown in Table
S5 and Table S6 are the KEGG enrichment results thus obtained
for the 155 selected target genes and the 162 selected between
genes, respectively. As we can see from the two tables, the 155
selected target genes were enriched on many cancer-related
pathways, such as pancreatic cancer, pathways in cancer, chronic
myeloid leukemia, colorectal cancer pathways, and other signaling
pathways, such as neurotrophin signaling pathway, T cell receptor
signaling pathway, B cell receptor signaling pathway, chemokine
signaling pathway. Likewise, the 162 selected between genes were
also enriched on cancer and signaling pathways, such as
pancreatic cancer, chemokine signaling pathway, axon guidance,
focal adhesion, and T cell receptor signaling pathway. We also
enriched the original 290 target genes and 684 between genes into
the KEGG pathways. The selected 155 target genes and selected
162 between genes had more enriched cancer-related pathways
and signaling pathways than the original 290 target genes and 684
between genes. Listed in Table S7 are the numbers of the top 20
enriched KEGG pathways for the 155 selected target genes, the
162 selected between genes, the original 290 target genes, and the
original 684 between genes.
The top five genes in the selected target genes were EFEMP1
(EGF-containing fibulin-like extracellular matrix protein 1), JAG2
(Protein jagged-2), TACSTD2 (Tumor-associated calcium signal
transducer 2), STAT3 (Signal transducer and activator of
transcription 3) and STAT1 (Signal transducer and activator of
transcription 1). EFEMP1 binds EGF receptor and activates
downstream signaling pathways. Expression of EFEMP1 promotes
angiogenesis and accelerates cancer growth [69]. EFEMP1 is a
novel tumor-suppressor gene found in hepatocellular carcinoma
[70]. JAG2 is involved in the mediation of Notch signaling and is
critical for cell development [71,72,73]. TACSTD2 encodes a
carcinoma-associated antigen and contributes to tumor pathogen-
esis [74]. STAT3 and STAT1 are members of the STAT (Signal
Transducers and Activators of Transcription) family of transcrip-
tion factors that regulates cell differentiation, growth and survival
[75]. In primary tumours, the STAT pathway is usually
dysregulated and causes increased angiogenesis, enhanced survival
of tumours and immunosuppression [76].
The top five genes in the selected between genes were PDIA3
(Protein disulfide-isomerase A3), LCP2 (Lymphocyte cytosolic
protein 2, also known as SLP-76, Src homology 2 domain
containing leukocyte protein of 76 kDa), IL23A (Interleukin-23
subunit alpha), SCAMP3 (Secretory carrier-associated membrane
protein 3) and ISG15 (Interferon-induced 17 kDa protein).
STAT3 ranked sixth in the selected between genes. PDIA3 is
part of the MHC (major histocompatibility complex) class I
peptide-loading complex, which is vital for the formation of
antigen conformation and export from the endoplasmic reticulum
Figure 3. The number of selected target genes of each HCV protein. The HCV proteins NS3, NS5A and CORE have the largest numbers of
target genes in the optimal set of the 155 selected target genes.
doi:10.1371/journal.pone.0034460.g003
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promoting T cell development and activation [78]. IL23A
activates the Jak-Stat signaling cascade, induces autoimmune
inflammation and may be important for tumorigenesis [79,80,81].
SCAMP3 can form association with the EGF Receptor [82].
ISG15 targets to diverse cellular pathways, such as JAK, STAT
and MAPK [83] and has antiviral activity [84].
The KEGG enrichment results for the top five target genes
(EFEMP1, JAG2, TACSTD2, STAT3 and STAT1) and for the
top five between genes (PDIA3, LCP2, IL23A, SCAMP3, ISG15)
are given in Table 2, where it can be seen that STAT1 and
STAT3 participated in several well-studied hepatocellular carci-
noma pathways, such as Jak-STAT signaling pathway, hepatitis C
pathway, and pathways in cancer. Interestingly, both the target
genes STAT1/STAT3 and the between gene IL23A were
involved in Jak-STAT signaling pathway; the latter is associated
with HCV clinical syndromes [22,85].
The advantages of between genes as biomarkers and
drug targets
The between genes are not only the coordinator of HCV that
triggers the disease-causing signaling, but also the carrier that
executes such order and actually causes the pathological changes.
Among the top five between genes, ISG15 was on the shortest path
of 289 HCV target gene pairs. It regulates and functions in diverse
cancer-related pathways [83]. It has been identified as an antiviral
Figure 4. The number of selected between genes for each of the HCV protein pairs. The following pairs have more than 80 selected
between genes: NS3_NS5A, CORE_NS3, F_NS3, E2_NS3, NS3_NS5B, CORE_NS5A and E1_NS3.
doi:10.1371/journal.pone.0034460.g004
Table 1. The enrichment of the 155 selected target genes and the 162 selected between genes on OncoDB.HCC genes.
Gene Set
Hyper geometric
test p value
Number of overlapped
genes with OncoDB.HCC Overlapped genes with OncoDB.HCC
Selected target genes 0.001984 15 BAX, CD81, CTGF, FAS, GRN, HSPA5, IGLL1, KRT19, NPM1, RAF1,
SERPINF2, SERPING1, SRC, THBS1, VIM
Selected between genes 1.25E-05 20 ALB, AR, CDC20, CDKN2A, COL4A1, CXCL12, DCN, DUSP1, E2F1,
ERBB2, GNAS, HSPA5, MAP2K1, MAPRE1, MMP2, MYC, PSMD4,
PTK2, ROBO1, SCAMP3
doi:10.1371/journal.pone.0034460.t001
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are responsible for the initiation and progression of hepatocellular
cirrhosis and carcinoma. They have closer relationship with the
pathological changes during the transformation of hepatocellular
cirrhosis and carcinoma than HCV proteins or their target genes.
The target genes may indicate the early response of HCV
infection, but the between genes can more accurately reflect the
post-infection pathological processes and hence be used to serve as
a better biomarker. The classification accuracy of the 162 selected
between genes was 0.960, higher the accuracy of the 155 selected
target genes, 0.944. The accuracy of the top five between genes
was 0.815, also higher the accuracy of the top five target genes,
0.782. Classifier based on the between genes performed better
than the classifier based on the target genes. Since the between
genes play important roles in the course of both initiating the
disease and its aggravation, they may become a drug target for
both the preventive and therapeutic purposes, like the between
gene ISG15 already did [84].
Supporting Information
Figure S1 The IFS curve of the combined gene set. (A) The IFS
curve of the combined gene set, between genes and target genes.
The black, red and blue lines represent the IFS curve of the
combined gene set, between genes and target genes, respectively.
The curve of between genes is consistently higher than the curve of
target genes. The curve of combined gene set is twisted with the
curve of between genes. (B) The top ten gene IFS curve of the
combined gene set, between genes and target genes. The black,
red and blue lines represent the IFS curve of the combined gene
set, between genes and target genes, respectively. Within the top
ten genes, the highest accuracy of between genes is greater than
the accuracies of combined gene set and target genes.
(TIF)
Table S1 The IFS table of the target genes.
(XLSX)
Table S2 The IFS table of the between genes.
(XLSX)
Table S3 The selected 155 target genes.
(XLSX)
Table S4 The selected 162 between genes.
(XLSX)
Table S5 The KEGG enrichment result of the 155 selected
target genes.
(XLSX)
Table S6 The KEGG enrichment result of the 162 selected
between genes.
(XLSX)
Table S7 The top 20 enriched KEGG pathways for the 155
selected target genes, the 162 selected between genes, the original
290 target genes, and the 684 original between genes.
(XLSX)
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Table 2. The KEGG enrichment of the top five target genes (EFEMP1, JAG2, TACSTD2, STAT3 and STAT1) and the top five between
genes (PDIA3, LCP2, IL23A, SCAMP3, ISG15).
KEGG Corrected hyper geometric p value Genes
04630 :Jak-STAT signaling pathway 0.000327 STAT1,IL23A,STAT3
05212 :Pancreatic cancer 0.002516 STAT1,STAT3
05160 :Hepatitis C 0.003061 STAT1,STAT3
05162 :Measles 0.003619 STAT1,STAT3
05145 :Toxoplasmosis 0.00439 STAT1,STAT3
04062 :Chemokine signaling pathway 0.004439 STAT1,STAT3
05152 :Tuberculosis 0.004603 STAT1,IL23A
04380 :Osteoclast differentiation 0.005503 LCP2,STAT1
05200 :Pathways in cancer 0.011662 STAT1,STAT3
04330 :Notch signaling pathway 0.033518 JAG2
05140 :Leishmaniasis 0.034105 STAT1
04664 :Fc epsilon RI signaling pathway 0.034608 LCP2
04622 :RIG-I-like receptor signaling pathway 0.036039 ISG15
05221 :Acute myeloid leukemia 0.036899 STAT3
05323 :Rheumatoid arthritis 0.037517 IL23A
04612 :Antigen processing and presentation 0.03827 PDIA3
04620 :Toll-like receptor signaling pathway 0.040087 STAT1
04660 :T cell receptor signaling pathway 0.040175 LCP2
04920 :Adipocytokine signaling pathway 0.040873 STAT3
04650 :Natural killer cell mediated cytotoxicity 0.045794 LCP2
doi:10.1371/journal.pone.0034460.t002
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